Every Angle Covered.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Social Media
Donald Trump
NATO
Taxes
European Union
Education
Soccer
Cryptocurrency
Stock Markets
Climate Change
Corruption
Published • loading... • Updated

36-month results from phase 1/2a clinical study of RG6501 released

Summary by ophthalmologytimes.com
New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
ophthalmologytimes.comophthalmologytimes.com

36-month results from phase 1/2a clinical study of RG6501 released

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ophthalmologytimes.com broke the news in on Thursday, June 26, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal